Chimerix reports preliminary data showing antiviral brincidofovir improves survival in adenovirus

9 October 2014

Antiviral biopharma company Chimerix (Nasdaq: CMRX) has reported preliminary data indicating that its investigational antiviral brincidofovir improved survival for patients with adenovirus in the open-label pilot portion of the Phase III trial.

The preliminary survival analysis data is based on 48 evaluable patients from the ongoing trial showed a mortality rate of 35% compared with historic rates of up to 80% mortality in the first month after diagnosis.

A majority of trial subjects also had a suppression or clearance of adenovirus from the blood. There is currently no approved treatment for adenovirus, and the infection can progress rapidly in patients with a weakened immune system due to disease or medications.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK